This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Hypophosphatemic Rickets in Norway

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Haukeland University Hospital Identifier:
First received: January 26, 2010
Last updated: August 30, 2016
Last verified: August 2016
The purpose of the study is to do a follow-up survey of all individuals with hereditary hypophosphatemia in Norway, focusing on manifestations in childhood and adolescence. The investigators also want to study phenotype-genotype associations, and look for new genes, in all forms of hereditary hypo and hyperphosphatemia.

Condition Intervention
Hypophosphatemia, Familial Rickets Hyperphosphatemia Dietary Supplement: Alfacalcidol; phosphate. Drug: Sevelamer

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Hypophosphatemic Rickets in Norway

Resource links provided by NLM:

Further study details as provided by Haukeland University Hospital:

Primary Outcome Measures:
  • Growth [ Time Frame: Up to 18 years ]
    Change i height z-score from time of diagnosis to last registered consultation.

Biospecimen Retention:   Samples With DNA
EDTA plasma, serum, urine

Estimated Enrollment: 80
Study Start Date: December 2009
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
hereditary hypophosphatemia
Norwegian patients with hereditary hypophosphatemia.
Dietary Supplement: Alfacalcidol; phosphate.
Individual dosage form and dosage depending on phenotype and underlying cause.
Hereditary hyperphosphatemia
Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
Drug: Sevelamer
Pills. Individual dosage depending on clinical symptoms/phenotype.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The cohorts will be selected from Norwegian patients with hypophosphatemia and hyperphosphatemia.

Inclusion Criteria:

  • All patients in the Norwegian population with hereditary hypophosphatemia, with or without rickets
  • Patients in the Norwegian population with hereditary hyperphosphatemia

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01057186

Haukeland University Hospital, Childrens departement
Bergen, Norway, 5021
Sponsors and Collaborators
Haukeland University Hospital
Study Director: Robert Bjerknes, Professor, MD, PhD Haukeland University Hospital, Pediatric department
  More Information

Responsible Party: Haukeland University Hospital Identifier: NCT01057186     History of Changes
Other Study ID Numbers: 21922
Study First Received: January 26, 2010
Last Updated: August 30, 2016

Additional relevant MeSH terms:
Rickets, Hypophosphatemic
Familial Hypophosphatemic Rickets
Hypophosphatemia, Familial
Phosphorus Metabolism Disorders
Metabolic Diseases
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Calcium Metabolism Disorders
Vitamin D Deficiency
Deficiency Diseases
Nutrition Disorders
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Urologic Diseases
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents processed this record on September 20, 2017